Introduction: The SGLT-2 inhibitors (SGLT-2i) are a newer anti-diabetic drugs. Their use has tremendously increased due to their favorable profile but they are also the focus of attention because of their side effect of euglycemic diabetic ketoacidosis (euDKA), which is challenging to diagnose...
综上所述,SGLT-2i可通过多种途径使酮体生成增加、清除率下降,导致酮体蓄积而引发酮症酸中毒,由于SGLT-2i可增加尿糖排泄,患者在发生酮症酸中毒时,血糖往往不超过13.9mmoL/L,被称为“血糖不高的DKA”,容易被忽视或漏诊。建议在使用SGLT-2i期间,若患者出现如恶心...
使用 SGLT2i 时发生 DKA 的患者症状不典型,血糖通常不超过 13.9 mmol/L,为非高血糖性 DKA,也称血糖正常的酮症酸中毒(euDKA)。 有Meta 分析检索了 PubMed 和 EMBASE 数据库 2010 年 1 月至 2020 年 8 月的病例报告和临床试验中接...
A case series detailing the association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and a serious side effect of euglycemic diabetic ketoacidosis (DKA) in nine patients, seven of whom had type 1 diabetes and two type 2 diabetes, has beenpublished onlineJune 15 inDiabetes Care, by ...
Euglycemic diabetic ketoacidosis (EuDKA) secondary to Sodium-glucose co-transporter-2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2D) is a rare but increasingly reported phenomenon. Not much is known about the burden of EuDKA in patients on SGLT2i or the associated factors. This retrosp...
Keywords:SGLT2inhibitors?Euglycemicdiabeticketoacidosis 0 引言 钠- 葡萄糖协同转运蛋白 2 ( Sodium~glucosecotransporter2?SGLT2) 抑制剂是一种新型的口服 降糖药物?临床上用于糖尿病患者的治疗?在减轻 体重和降低低血糖的发生率方面有较好的效果? 欧盟和美国批准上市的 SGLT2 抑制剂包括坎格 列净 ( Canagliflozin)...
SGLT2 inhibitors have been associated with an increased risk of euglycemic diabetic ketoacidosis (DKA).71,72 An observational study of patients in the United States identified several risk factors for hospitalization owing to SGLT2 inhibitor-associated DKA, including use of digoxin or medication for ...
【摘要】钠-葡萄糖转运体2抑制剂(sodium-glucose transporter 2 inhibitors,SGLT2i)是一类新型口服降糖药,临床试验显示,该类药物不但对2型糖尿病患者有独立于降糖作用的心肾保护作用,而且对非糖尿病慢性肾脏病(chronic kidney disease,CKD)患者也可改善心肾结局,且总体安全性表现良好。目前SGLT2i已成为CKD患者心肾保...
Sodium-glucose co-transporter-2 (SGLT2) inhibitors, integral in type 2 diabetes mellitus (T2DM) management, are not without risks, with reported adverse effects including euglycemic diabetic ketoacidosis (EDKA). We present a case of a 75-year-old female with T2DM on canagliflozin, who developed...
Both heart failure and diuretic or SGLT2 inhibitor use increase fall risk in older adults. Diuretics and SGLT2 inhibitors not only have various fall-related adverse effects, which partly overlap (e.g. tendency to cause hypotension), but also differ: compared to SGLT2is, diuretics display more...